Business
Innovation Pharmaceuticals Brilacidin Received by U.S. Regional Biocontainment Laboratory; Testing Against Coronavirus (COVID-19)
Innovation Pharmaceuticals Brilacidin Received by U.S. Regional Biocontainment Laboratory; Testing Against Coronavirus (COVID-19).
About this update from Innovation Pharmaceuticals Inc.
[{"type":"text","content":"\n WAKEFIELD, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company has been notified by one of the 12 Regional Biocontainment Labs (RBLs) in the United States that it received shipment of Brilacidin, the Company’s defensin mimetic drug candidate, for testing against SARS-CoV-2, the specific coronavirus responsible for COVID-19. Brilacidin is immediately being placed into queue and the Company anticipates confirmation of the testing schedule as well as procedures for the studies later this week. Brilacidin and COVID-19 The coronavirus (COVID-19) outbreak poses a significant life-threatening and economic risk throughout the world. Over 109,500 cases have been diagnosed in at least 95 countries, resulting in 3,800 reported deaths, including 479 cases and 21 fatalities in the U.S. There are no effective approved therapies to treat COVID-19. Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials for other clinical indications, providing an established safety and efficacy profile, thereby potentially enabling it to rapidly help address the emerging worldwide coronavirus crisis, developed both as an intravenous medicine and as a vaccine. There is no assurance made or implied that testing Brilacidin for antiviral activity against any coronavirus will be successful. Alerts Sign-up for Innovation Pharmaceuticals email alerts is available at: http://www.ipharminc.com/email-alerts/ About Innovation Pharmaceuticals Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observe...